Concepedia

Daniel J. DeAngelo

DJ

Statistics

Publications

328

Citations

35.1K

H-Index

89

Active since

1989

Affiliations

Dana-Farber Cancer Institute(Current)

The University of Texas MD Anderson Cancer Center

Harvard University

Memorial Sloan Kettering Cancer Center

Brigham and Women's Hospital

Daniel J. DeAngelo is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.

Publications per year

1989–2025

328

Publications

328

A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

Jan Cools, Daniel J. DeAngelo, Jason Gotlib et al. · New England Journal of Medicine · 2003 · 1.7K citations · Full text

Life Sciences, Genetics, Hematology +15

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.5K citations · Full text

Medicine, Hematology, Oncology +13

MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

Yana Pikman, Benjamin H. Lee, Thomas Mercher et al. · PLoS Medicine · 2006 · 1.4K citations · Full text

Life Sciences, Genetics, Hematology +14

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 328